{"id":100389,"date":"2025-10-25T07:46:06","date_gmt":"2025-10-25T07:46:06","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/itm-announces-analyses-from-phase-3-compete-data-showing-higher-objective-response-rates-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-across-subgroups-of-patients-with-gep-nets-at-nanets-2025\/"},"modified":"2025-10-25T07:46:06","modified_gmt":"2025-10-25T07:46:06","slug":"itm-announces-analyses-from-phase-3-compete-data-showing-higher-objective-response-rates-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-across-subgroups-of-patients-with-gep-nets-at-nanets-2025","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/itm-announces-analyses-from-phase-3-compete-data-showing-higher-objective-response-rates-with-n-c-a-177lu-edotreotide-itm-11-vs-everolimus-across-subgroups-of-patients-with-gep-nets-at-nanets-2025\/","title":{"rendered":"ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\"><strong><strong>Austin, Texas,<\/strong> <strong>October 25, 2025<\/strong><\/strong> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x002_oIJL693jXVXmnvLYiEMFA7REl5eO2GaFKbLWgDrPlpYJVNsyq4LiRYczx8K_ytgvgF511WiX1ydM6AXTnYRdnGRYewhOC83v3XrsVGcSCooEsuN1gHHXvqMg-Sx\" rel=\"nofollow\" target=\"_blank\" title=\"ITM Isotope Technologies Munich SE\">ITM Isotope Technologies Munich SE<\/a><u> (ITM)<\/u>, a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results showed consistently higher objective response rates (ORR) and longer progression-free survival (PFS) across subgroups in patients treated with n.c.a. <sup>177<\/sup>Lu-edotreotide (also known as ITM-11 or <sup>177<\/sup>Lu-edotreotide) compared to everolimus, reinforcing its previously reported efficacy profile. Data were shared by study investigator, Jaume Capdevila, MD, PhD, in both oral and poster presentations at the 2025 North American Neuroendocrine Tumor Society (NANETS) Annual Multidisciplinary NET Medical Symposium, held October 23-25, 2025, in Austin, Texas.<\/p>\n<p>As previously announced at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YEObCTrdLEOwBWuYfY6VferLpxtAAATDnGzQomYcvUofyBl7nGCbcD60D_WcrAyBZTyDvWfVwcm6VgoMhVWavT7Yqu98E8WNjlRmGZqWqyif6v7dzifY3edeMQmI2agGDHYasU5680OPsyrkWhDTAdVRGZ6mANUvoFIkLobyd7thC-RoS7UroZlbRv0Qu5voDqCPqxjtgtFo0ecqxBNRMt3ARnKfvg4MwB1DU54FG8vnADUmTwjje9c7urnaOp0wNNREomtEFTKWAYPPFl7vHbgGShRzJaBDx41IBfgKcQuOXPMFbzW8h9P7Jnu5nZ48dt0_nr5k8e6A4vIS-dWrSRYBYD40S-a_KpQXmiiMOLgXbTUhDqwyWRlov_8dZDjm9-pBP1DPfqnRYONzOfNYPU7yTQDK8MChmtkfOE8GqTQwicI29FSYfjN_I0rraX77JeSpz7fvV31ssqlSS7dV_Q==\" rel=\"nofollow\" target=\"_blank\" title=\"ENETS 2025\">ENETS 2025<\/a>, the COMPETE trial, which included a total of 309 patients randomized to either <sup>177<\/sup>Lu-edotreotide (n=207) or everolimus (n=102), met its primary endpoint of progression-free survival, or PFS, (23.9 vs. 14.1 months; p=0.022; HR 0.67, 95% CI [0.48, 0.95]). At <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SllB8Ei_BhMG8NLAYobLXuPToEokpDezn3TFDl1bIO331m4jPL0FzpPlN_bx3XY7z0XDvX7aYvBgbnRTSkFS9tXV2DKZ_3Gro7hhTFkPFLVD2HJIPnS5Kh2A8LmPGIVxKv-tvlPUb-XzKbnkw7WRzwVUHdnOeAnuUXK-AJLls34rjejCL4Lc-G75lN-OhNEZGVIgGyMkzSkYzpo6mch5Ll8mGMj5rsiKH1kpnczFF0xmW1bjSr-TUHHkwUpLCYx2bZNJ3guJniA3CkxngOm973Zyzm8oc0-CT7T_gjP95Ih9uSUJE3pcqlh4OHrdPhQ3BBE1Y_n4o8zDCDu-4Jtj3o_WeDfIduqBJXem1wuix-H_ozFI4B0dKvxKUXtGJDruvLS6lCLtg5hqhB6EklDl3_VgRHn-rumMZZyukOTd6n89ldQ3WfhpGoFlnFlVIOycmoy9rmUH_lGSz_0soQ4j4w==\" rel=\"nofollow\" target=\"_blank\" title=\"ESMO 2025\">ESMO 2025<\/a>, ITM announced that the COMPETE trial also met a key secondary endpoint of objective response rate (ORR) (21.9% vs 4.2%, p&lt;0.0001).<\/p>\n<p>In this analysis of the COMPETE trial presented at NANETS 2025, the key findings showed:<\/p>\n<ul>\n<li style=\"margin-top:0cm; margin-bottom:0cm; text-align:justify;\">ORR was higher in patients in the <sup>177<\/sup>Lu-edotreotide arm vs. everolimus across subgroups, including those with pancreatic NETs, Grade 1 tumors, Grade 2 tumors, and those who had received prior therapy (2<sup>nd<\/sup> line); post-hoc analysis<\/li>\n<li style=\"margin-top:0cm; margin-bottom:10pt; text-align:justify;\">Although data is still maturing, there was a preliminary trend of longer median overall survival (OS) in the <sup>177<\/sup>Lu-edotreotide arm vs. everolimus in most patient subgroups\n<p>\u00a0<\/p>\n<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse; width:900px; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"3\" style=\"width:623.8px;;text-align: center ;  vertical-align: middle; border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"> <strong>ORR and OS Subgroup Analyses Based on Blinded Independent Central Review (BICR): Phase 3 COMPETE Trial<br \/><\/strong><sup>177<\/sup>Lu-edotreotide (n=207 patients) vs. everolimus (n=102 patients) <\/td>\n<\/tr>\n<tr>\n<td style=\"width:170.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">\u00a0 <\/td>\n<td style=\"width:217.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"> <strong>Objective Response Rate (ORR);<\/strong> post-hoc analysis <\/td>\n<td style=\"width:236.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"> <strong>Overall Survival (OS)<\/strong> <\/td>\n<\/tr>\n<tr>\n<td style=\"width:170.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"> <strong>Primary Tumor Origin<br \/><\/strong>Gastroenteric NET<\/p>\n<p>Pancreatic NET <\/p>\n<\/td>\n<td style=\"width:217.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">6.0 % v. 5.0%<\/p>\n<p>33.3% v. 3.6% <\/p>\n<\/td>\n<td style=\"width:236.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">63.4 months v. 58.7 months<br \/>(p value = 0.799)<\/p>\n<p>65.7 months v. 49.3 months<br \/>(p value=0.263) <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:170.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"> <strong>Tumor Grade <sup>1<br \/><\/sup><\/strong>Grade 1<\/p>\n<p>Grade 2 <\/p>\n<\/td>\n<td style=\"width:217.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">15.8% v. 3.3%<\/p>\n<p>28.3% v. 3.1% <\/p>\n<\/td>\n<td style=\"width:236.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">NR<sup>2<\/sup> v. NR<br \/>(p value=0.702)<\/p>\n<p>56.7 months vs. 41.4 months<br \/>(p value=0.082) <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:170.14px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"> <strong>Prior Medical Therapy<br \/><\/strong>Treatment-na\u00efve (1<sup>st<\/sup> line)<\/p>\n<p>Prior therapy (2<sup>nd<\/sup> line) <\/p>\n<\/td>\n<td style=\"width:217.34px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">17.9% v. 5.9%<\/p>\n<p>22.5% v. 3.8% <\/p>\n<\/td>\n<td style=\"width:236.2px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">57.4 months v. NR<br \/>(p value= 0.016)<\/p>\n<p>63.4 months v. 43.4 months<br \/>(p value=0.018) <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td colspan=\"3\" style=\"width:623.8px;;border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"> <sup><em>1<\/em><\/sup><em>Central assessment according to WHO classification, <sup>2<\/sup>Not reached\u00a0<\/em> <\/td>\n<\/tr>\n<\/table>\n<p><em>\u201cWe are encouraged by the positive trends we see in PFS extension and higher ORR for\u00a0<\/em><em><sup>177<\/sup>Lu-edotreotide compared to everolimus in these patient subgroups. These results strengthen the existing data set for Lu-edotreotide\u2019s<\/em><em> potential as a new therapeutic option for people living with inoperable GEP-NETs,\u201d<\/em> said <strong>Dr. Capdevila, senior medical oncologist at Vall d&#8217;Hebron University Hospital, Barcelona<\/strong>.\u00a0<\/p>\n<p>ITM also announced real-world clinical and meta-analysis data\u00a0in patients with a range of neuroendocrine tumors at NANETS.<\/p>\n<p>In early October, ITM presented dosimetry\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CT6ObY_3U4exntgte8ECF3wfzVKYJR2b7hvwShd0IPbWP8ELpn6qXiaxzoulqvTPOnElS8RNUV673Re5-3N7TGJHlzrNrFZeuj5h-e23QF39O93113RI8Hze8dwcK3bsfZ6WR-HyqzzyYRBcYyxFqxWM9mitUnHhuU0TV57hCpyMqd53q1d21oKTw38xpMVoMD5M9lZuuCm5v3fTC7esjKqfZBbYtEd31cbRsLTsCbVQyCDtNhIr9XBaBxaZ6dyeHsSDj10qLSX7daS3mPKI8qkU4HtzNT3QfDwutZqWu1m1VlYL1LRM_30lutxxPj2kQ78ACgUYxoSvwVO92F4GRTBq2Jg2vuvrn5BBP1BkonlxJM1ZK5nUlbsH6BftxQ24OvfI04squ4b5InZnWFq0fUwmDzyRo8rJAMKi-6BBEi8NZhQmEhmFGeO1-S69ezyz5C2GrRPdSoux-TiEpOubaQ==\" rel=\"nofollow\" target=\"_blank\" title=\"data\">data<\/a> from the COMPETE trial at the European Association of Nuclear Medicine (EANM) Annual Congress in Barcelona, Spain. The data showed that <sup>177<\/sup>Lu-edotreotide delivered targeted radiation to tumors while minimizing exposure to healthy tissue, supporting its efficacy and safety profile.<\/p>\n<p><em>\u201cThese additional subgroup data\u00a0reinforce and extend evidence from the COMPETE Phase 3 trial, supporting <sup>177<\/sup>Lu-edotreotide\u2019s potential<\/em><em> as a promising radiopharmaceutical therapy for neuroendocrine tumors if approved,\u201d<\/em> said <strong>Dr. Andrew Cavey, chief executive officer of ITM<\/strong>.\u00a0<\/p>\n<p><strong><u>Oral Presentation Details<\/u><\/strong><br \/><strong>Title: <\/strong>Efficacy of <sup>177<\/sup>Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)<br \/><strong>Date and Time: <\/strong>October 24, 2025, 3:35-4:50 pm Central Time <br \/><strong>Session: <\/strong>Part II Featured Abstracts| Access to New Treatments &#8211; How can we bring innovative treatments to patients more quickly and effectively? <br \/><strong>Presenter:<\/strong> Jaume Capdevila, MD, PhD, senior researcher, department of Medical Oncology, Vall d&#8217;Hebron University Hospital &amp; Vall d&#8217;Hebron Institute of Oncology<\/p>\n<p><strong><u>Poster Presentation Details:<br \/><\/u><\/strong><strong>Title:\u00a0<\/strong>Efficacy of <sup>177<\/sup>Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)<br \/><strong>Date and Time: <\/strong>Friday, October 24, 5:15-6:30 pm Central Time<br \/><strong>Session: <\/strong>NANETS Poster Tour<br \/><strong>Presenter: <\/strong>Dr. Jaume Capdevila, Vall d&#8217;Hebron University Hospital, Barcelona. <\/p>\n<p><strong>Title:<\/strong> First-line Treatment with <sup>177<\/sup>Lu-edotreotide ([<sup>177<\/sup>Lu]Lu-DOTATOC) in patients with NETs: a Swiss NET Registry Analysis<br \/><strong>Date and Time<\/strong>: Friday, October 24, 5:15-6:30 pm Central Time<br \/><strong>Session: <\/strong>NANETS Poster Tour\u00a0<br \/><strong>Presenter: <\/strong>Dr. Guillaume Nicolas, University Hospital Basel<\/p>\n<p><strong><strong>Title:<\/strong><\/strong> Efficacy and safety of <sup>177<\/sup>Lu-edotreotide ([<sup>177<\/sup>Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors (NETs) \u2013 a systematic literature review (SLR) and meta-analysis<br \/><strong>Date and Time<\/strong>: Friday, October 24, 5:15-6:30 pm Central Time<br \/><strong>Session<\/strong><em>: <\/em>NANETS Poster Tour<br \/><strong>Presenter<\/strong>: Dr. Julia G Fricke, University Hospital Basel<\/p>\n<p><strong>About the COMPETE Trial<br \/><\/strong>The COMPETE trial (NCT03049189) evaluated\u00a0<sup>177<\/sup>Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with\u00a0<sup>177<\/sup>Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. <sup>177<\/sup>Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors.<br \/><strong><br \/>About ITM Isotope Technologies Munich SE\u00a0<br \/><\/strong>ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians, and our partners through excellence in development, production, and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company\u2019s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kEQpU4kddQ73Kqc_9N0OQ-n4vKBxv3dj7DuzLtlfwvmZMFlCAHKIMptRdJC7_c21-wRycCPowu0L4yvHqhm3fC5vUSauYHQ0knUksB6FnkaLTOemIakE3z4lLiT-2R_t\" rel=\"nofollow\" target=\"_blank\" title=\"www.itm-radiopharma.com\">www.itm-radiopharma.com<\/a><\/p>\n<p><strong>ITM Contacts:<br \/><\/strong>Corporate Communications<br \/>Kathleen Noonan\/Julia Westermeir<br \/>Phone: +49 89 329 8986 1500<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9F8_BB66DjBLIVvgtYDw6NxgnhBzIvas_k0QBUYSfdCXbphNz8raL0GPqcU6e0rtcCSDeir1glDGS3SxTHE5e7dspRrLs8fr6Vrk7fjci6XzcAm4HYHfTuqVU5oTrqnwIwoV-v7txMTu9QUsrWlHmQ==\" rel=\"nofollow\" target=\"_blank\" title=\"communications@itm-radiopharma.com\">communications@itm-radiopharma.com<\/a><\/p>\n<p>Investor Relations<br \/>Ben Orzelek<br \/>Phone: +49 89 329 8986 1009<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=80Jro0g5rGlch8ZZt7JSnntIMkNQ9ywEr-0aE4bVq9zyGc-gBa8OjghZt5fP6rIQM5LINXq3qKM3ezmOyQDeCmEIQSbhfijoXcptHP08tRsOHneBaLHUKpVqiMiNS0X3IJHI54k614QRBvueVrAmws9yELu_2DGAY4hQMvrAYTl3ClsIZmJKpzcHpJTXl3iA0yHJhLfApJnC7FmefLwWNdx9JKJDIQSyv-0JMeQq8tTfHXYM_mbf__kS6XmdhHzGLy4rxPPUSG8A1iPfqlwL80Rs6J9fhyKMwcRIWr_i4ZDmtslIRoBHSyxNo3gupS0M\" rel=\"nofollow\" target=\"_blank\" title=\"investors@itm-radiopharma.com\">investors@itm-radiopharma.com<\/a><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=QU-ErubuQuGCLG5aX-PG61TfOyLYoHj4LgtlSCq-fi03KVT9VCG9ywvgYVFNAzE-BRmve1joZZ6B0hlHUtLs7E4DjCa6jiX1CJDw-FQ2X0GrPjCvCzVbrXGswhdUai9a2TcNrDrx3YDa_PTKkGL0E_syFkn3eu1_erBXhJdyIibeJ1LLVLXsu7QAZFVK4ujH\" title=\"20251025_ITM_NANETS 2025 COMPETE\" rel=\"nofollow\">20251025_ITM_NANETS 2025 COMPETE<\/a>\n      <\/li>\n<\/ul>\n<p>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>Austin, Texas, October 25, 2025 \u2013 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade 1 or Grade 2 somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Results showed consistently higher objective response rates (ORR) and longer progression-free survival (PFS) across [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":100390,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/3411c2bd-01a5-4d06-ad90-4a6e168bad61","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-100389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/100389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=100389"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/100389\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/100390"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=100389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=100389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=100389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}